

JAN 16 2006

PTO/SB/21 (09-04)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

9

Application Number

09/877,374

Filing Date

June 8, 2001

First Named Inventor

Jeffrey C Rapp

Art Unit

1632

Examiner Name

Thaia N. Ton

Attorney Docket Number

AVI-007

**ENCLOSURES**

(Check all that apply)



Fee Transmittal Form



Fee Attached



Amendment/Reply



After Final



Affidavits/declaration(s)



Extension of Time Request



Express Abandonment Request



Information Disclosure Statement



Certified Copy of Priority Document(s)

Reply to Missing Parts/  
Incomplete ApplicationReply to Missing Parts  
under 37 CFR 1.52 or 1.53

Drawing(s)



Licensing-related Papers



Petition

Petition to Convert to a  
Provisional Application

Power of Attorney, Revocation



Change of Correspondence Address



Terminal Disclaimer



Request for Refund



CD, Number of CD(s) \_\_\_\_\_



Landscape Table on CD



After Allowance Communication to TC

Appeal Communication to Board  
of Appeals and InterferencesAppeal Communication to TC  
(Appeal Notice, Brief, Reply Brief)

Proprietary Information



Status Letter

Other Enclosure(s) (please identify  
below):

Remarks

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name

AviGenics, Inc.

Signature

Printed name

Kyle Yesland

Date

January 16, 2006

Reg. No.

45526

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature

Typed or printed name

Kyle Yesland

Date

January 16, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

JAN 16 2006

Appl. No. 09/877,374  
Reply to Office action of November 16, 2005

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE PATENT**

Appl. No. : 09/877,374  
Applicant : Jeffrey C Rapp  
Filed : June 8, 2001  
Title : Production of a Monoclonal Antibody by a Transgenic Chicken  
  
TC/A.U. : 1632  
Examiner : Thaian N. Ton  
  
Docket No. : AVI-007N

I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office or is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on or before:

Date January 16, 2006  
Signature [Signature]  
Name Lyle Vestland

Mail Stop: Amendment  
Honorable Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**AMENDMENT**

Sir:

The following is in response to the Office action dated November 16, 2005:

**Amendment to the Title** begins on page 2 of this paper.

**Amendments to the Claims** are reflected in the listing of claims which begins on page 3 of this paper.

**Remarks/Arguments** begin on page 8 of this paper.

Appl. No. 09/877,374  
Reply to Office action of November 16, 2005

**Amendment to the Title:**

Please replace the title beginning at page 1, line 2 of the application with the following amended title:

~~PRODUCTION OF A MONOCLONAL ANTIBODY BY A TRANSGENIC CHICKEN~~ PRODUCTION  
OF ANTIBODIES